pioglitazone has been researched along with Acute Ischemic Stroke in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone use is associated with a lower risk of dementia in patients with DM, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in patients with DM." | 8.31 | Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke. ( Choi, DW; Ha, J; Kim, E; Kim, KJ; Kim, KY; Nam, CM, 2023) |
| "In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF." | 8.31 | Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. ( Baik, M; Jeon, J; Kim, J; Yoo, J, 2023) |
| "Using longitudinal nationwide data from the 2002-2017 Korean National Health Insurance Service DM cohort, we analyzed the association between pioglitazone use and incidence of primary ischemic stroke using a nested case-control study." | 8.02 | Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study. ( Choi, DW; Ha, J; Kim, E; Kim, KY; Nam, CM, 2021) |
| "Participants were enrolled in the Insulin Resistance Intervention after Stroke trial, which examined the insulin sensitiser, pioglitazone versus placebo for prevention of stroke and myocardial infarction after ischaemic stroke or transient ischaemic attack." | 5.22 | Taking care of volunteers in a stroke trial: a new assisted-management strategy. ( Cote, R; Ford, GA; Furie, KL; Inzucchi, SE; Kernan, WN; Sico, JJ; Spence, JD; Stuart, AC; Tanne, D; Tayal, AH; Viscoli, CM, 2016) |
| "Pioglitazone use is associated with a lower risk of dementia in patients with DM, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in patients with DM." | 4.31 | Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke. ( Choi, DW; Ha, J; Kim, E; Kim, KJ; Kim, KY; Nam, CM, 2023) |
| "In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF." | 4.31 | Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. ( Baik, M; Jeon, J; Kim, J; Yoo, J, 2023) |
| "Using longitudinal nationwide data from the 2002-2017 Korean National Health Insurance Service DM cohort, we analyzed the association between pioglitazone use and incidence of primary ischemic stroke using a nested case-control study." | 4.02 | Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study. ( Choi, DW; Ha, J; Kim, E; Kim, KY; Nam, CM, 2021) |
| "The treatment of reperfusion injury after ischemic stroke remains unsatisfactory since the blood-brain barrier (BBB) prevents most neuroprotective agents from entering the brain." | 1.91 | Bacteria-Derived Outer-Membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke Therapy. ( Guo, X; Huang, X; Pan, J; Wang, Z; Xue, J; Zhang, S; Zhou, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 8 (88.89) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, Y | 1 |
| Zuo, W | 1 |
| Yin, L | 1 |
| Gu, T | 1 |
| Wang, S | 1 |
| Fang, Z | 1 |
| Wang, B | 1 |
| Dong, H | 1 |
| Hou, W | 1 |
| Zuo, Z | 1 |
| Deng, J | 1 |
| Ha, J | 2 |
| Choi, DW | 2 |
| Kim, KJ | 1 |
| Kim, KY | 2 |
| Nam, CM | 2 |
| Kim, E | 3 |
| Yoo, J | 1 |
| Jeon, J | 1 |
| Baik, M | 1 |
| Kim, J | 1 |
| Feng, Q | 1 |
| Lewis, A | 1 |
| Galetta, S | 1 |
| Pan, J | 1 |
| Wang, Z | 1 |
| Huang, X | 1 |
| Xue, J | 1 |
| Zhang, S | 1 |
| Guo, X | 1 |
| Zhou, S | 1 |
| Stuart, AC | 1 |
| Sico, JJ | 1 |
| Viscoli, CM | 1 |
| Tayal, AH | 1 |
| Inzucchi, SE | 1 |
| Ford, GA | 1 |
| Furie, KL | 1 |
| Cote, R | 1 |
| Spence, JD | 1 |
| Tanne, D | 1 |
| Kernan, WN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Insulin Resistance Intervention After Stroke (IRIS) Trial[NCT00091949] | Phase 3 | 3,876 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fatal or non-fatal acute myocardial infarction or unstable angina (NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 136 |
| Placebo | 146 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
Change in modified mental status examination (3MS) score from baseline to exit. Theoretical range of 3MS scores is 0-100. Baseline scores ranged from 22-100. (NCT00091949)
Timeframe: Annual measures from baseline to exit (up to 5 years)
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone | 0.27 |
| Placebo | 0.29 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 73 |
| Placebo | 149 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 127 |
| Placebo | 154 |
(NCT00091949)
Timeframe: Up to 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 175 |
| Placebo | 228 |
1 trial available for pioglitazone and Acute Ischemic Stroke
| Article | Year |
|---|---|
Taking care of volunteers in a stroke trial: a new assisted-management strategy.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Biomarkers; Blood Coagulation; Blood Pressu | 2016 |
8 other studies available for pioglitazone and Acute Ischemic Stroke
| Article | Year |
|---|---|
Pioglitazone attenuates ischaemic stroke aggravation by blocking PPARĪ³ reduction and inhibiting chronic inflammation in diabetic mice.
Topics: Animals; Brain Ischemia; Diabetes Mellitus, Experimental; Inflammation; Ischemic Stroke; Mice; NLR F | 2022 |
Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Ischemic Stroke; Myocardial Ischemia; Piogli | 2023 |
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin | 2023 |
Reader Response: Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
Topics: Dementia; Diabetes Mellitus; Humans; Ischemic Stroke; Patients; Pioglitazone | 2023 |
Editors' Note: Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
Topics: Dementia; Diabetes Mellitus; Humans; Ischemic Stroke; Patients; Pioglitazone | 2023 |
Author Response: Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
Topics: Dementia; Diabetes Mellitus; Humans; Ischemic Stroke; Patients; Pioglitazone | 2023 |
Bacteria-Derived Outer-Membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke Therapy.
Topics: Bacteria; Extracellular Vesicles; Humans; Ischemic Stroke; Neutrophils; Pioglitazone; Reperfusion In | 2023 |
Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; | 2021 |